Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2 Not yet recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2 Recruiting

74 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

54 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06202313 2024-01-11

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Not yet recruiting

128 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03579472 2022-10-31

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1 Terminated

38 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05402722 2022-06-02

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

Phase 1/2 Completed

258 enrolled 18 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Phase 3 Completed

622 enrolled 26 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

265 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

160 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04502680 2020-08-11

EMBRAVE-001

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02225470 2018-08-28

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Phase 3 Completed

530 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Phase 1 Unknown

1 enrolled

Breast

Triple Negative Breast Neoplasms